- Home
- DTIL
as of 01-23-2026 3:59pm EST
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | DURHAM |
| Market Cap: | 97.7M | IPO Year: | 2019 |
| Target Price: | $60.00 | AVG Volume (30 days): | 251.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -8.32 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.75 - $8.82 | Next Earning Date: | 11-03-2025 |
| Revenue: | $698,000 | Revenue Growth: | -99.07% |
| Revenue Growth (this year): | -86.43% | Revenue Growth (next year): | 34.30% |
AI-Powered DTIL Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Precision BioSciences Inc. (DTIL)
President and CEO
Avg Cost/Share
$4.17
Shares
34,799
Total Value
$145,111.83
Owned After
196,154
SEC Form 4
General Counsel and Secretary
Avg Cost/Share
$4.03
Shares
8,854
Total Value
$35,681.62
Owned After
44,715
SEC Form 4
Chief Research Officer
Avg Cost/Share
$4.03
Shares
10,200
Total Value
$41,106.00
Owned After
110,184
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$4.03
Shares
15,213
Total Value
$61,308.39
Owned After
106,448
SEC Form 4
Director
Avg Cost/Share
$4.72
Shares
3,000
Total Value
$14,160.00
Owned After
23,883
SEC Form 4
Director
Avg Cost/Share
$4.70
Shares
2,700
Total Value
$12,690.00
Owned After
19,478
SEC Form 4
Director
Avg Cost/Share
$4.97
Shares
1,381
Total Value
$6,863.57
Owned After
23,346
SEC Form 4
General Counsel and Secretary
Avg Cost/Share
$6.49
Shares
665
Total Value
$4,315.85
Owned After
44,715
SEC Form 4
Chief Financial Officer
Avg Cost/Share
$6.49
Shares
1,303
Total Value
$8,456.47
Owned After
106,448
SEC Form 4
President and CEO
Avg Cost/Share
$6.49
Shares
3,409
Total Value
$22,124.41
Owned After
196,154
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Amoroso Michael | DTIL | President and CEO | Jan 22, 2026 | Sell | $4.17 | 34,799 | $145,111.83 | 196,154 | |
| Scimeca Dario | DTIL | General Counsel and Secretary | Jan 21, 2026 | Sell | $4.03 | 8,854 | $35,681.62 | 44,715 | |
| SMITH J. JEFFERSON | DTIL | Chief Research Officer | Jan 21, 2026 | Sell | $4.03 | 10,200 | $41,106.00 | 110,184 | |
| Kelly John Alexander | DTIL | Chief Financial Officer | Jan 21, 2026 | Sell | $4.03 | 15,213 | $61,308.39 | 106,448 | |
| Germano Geno J | DTIL | Director | Dec 16, 2025 | Buy | $4.72 | 3,000 | $14,160.00 | 23,883 | |
| Frankel Stanley | DTIL | Director | Dec 16, 2025 | Buy | $4.70 | 2,700 | $12,690.00 | 19,478 | |
| Brown Melinda | DTIL | Director | Dec 15, 2025 | Buy | $4.97 | 1,381 | $6,863.57 | 23,346 | |
| Scimeca Dario | DTIL | General Counsel and Secretary | Nov 3, 2025 | Sell | $6.49 | 665 | $4,315.85 | 44,715 | |
| Kelly John Alexander | DTIL | Chief Financial Officer | Nov 3, 2025 | Sell | $6.49 | 1,303 | $8,456.47 | 106,448 | |
| Amoroso Michael | DTIL | President and CEO | Nov 3, 2025 | Sell | $6.49 | 3,409 | $22,124.41 | 196,154 |
Compare DTIL vs Leading Stocks
See how DTIL stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "DTIL Precision BioSciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.